Parkinson's disease mutant Miro1 causes mitochondrial dysfunction and dopaminergic neuron loss

Axel Chemla1, Giuseppe Arena1, Ginevra Sacripanti1

  • 1Luxembourg Centre for Systems Biomedicine (LCSB), University of Luxembourg, L-4362 Esch-sur-Alzette, Luxembourg.

PubMed

Insights

Mutant Miro1 protein is a key driver of Parkinson's disease (PD) pathology, causing mitochondrial dysfunction, alpha-synuclein accumulation, and dopaminergic neuron loss in cellular and animal models.

Area of Science:

  • Neuroscience
  • Genetics
  • Cell Biology

Background:

  • Parkinson's disease (PD) pathogenesis involves complex neurodegeneration, with mitochondrial dysfunction increasingly implicated.
  • Miro1 (RHOT1 gene) is crucial for mitochondrial homeostasis, including transport, mitophagy, and calcium buffering.
  • Genetic variants in Miro1 are linked to PD, highlighting its potential role.

Purpose of the Study:

  • To investigate Miro1-dependent mechanisms in PD neurodegeneration using patient-derived models and knock-in mice.
  • To elucidate the molecular pathways affected by Miro1 mutations in PD.

Main Methods:

  • Utilized induced pluripotent stem cell (iPSC)-derived models (midbrain organoids, dopaminergic neurons) from PD patients with a Miro1 mutation (p.R272Q) and controls.
  • Employed knock-in mice expressing the Miro1 p.R285Q mutation (orthologue of human p.R272Q).
  • Assessed oxidative stress, mitochondrial bioenergetics, cellular metabolism, alpha-synuclein levels, calcium homeostasis, and neuronal loss.

Main Results:

  • The p.R272Q Miro1 mutation induced oxidative stress, impaired mitochondrial function, and altered metabolism in cellular models.
  • Mutant Miro1 led to increased alpha-synuclein and reduced dopaminergic neuron survival.
  • Disrupted calcium homeostasis by the mutation activated calpain proteases, cleaving alpha-synuclein.
  • Knock-in mice showed phosphorylated alpha-synuclein, dopaminergic neuron loss, and behavioral deficits.

Conclusions:

  • Mutant Miro1 is sufficient to recapitulate key PD phenotypes in vitro and in vivo.
  • Miro1 plays a pivotal role in PD pathogenesis through mitochondrial dysfunction and alpha-synuclein dysregulation.
  • Miro1 mutations offer a valuable model for studying PD mechanisms and potential therapeutic targets.

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
447
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
192
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.2K